Listen
MIDAZOLAM AGUETTANT (midazolam) - Sedation in palliative care.
Reason for request
Summary of opinion
Favourable opinion for reimbursement in the indication sedation in palliative care.
No clinical added value compared to the other generic medicinal products containing midazolam for injection already available in this indication (MIDAZOLAM ACCORD, solution for injection and MIDAZOLAM VIATRIS, solution for injection or rectal use).
Clinical Benefit
| Substantial |
The Committee considers that the clinical benefit of MIDAZOLAM AGUETTANT (midazolam) solution for injection is substantial in sedation in palliative care. |
Clinical Added Value
| no clinical added value |
This medicinal product provides no clinical added value (CAV V) compared to the other generic medicinal products containing midazolam for injection already listed (MIDAZOLAM ACCORD solution for injection, and MIDAZOLAM VIATRIS solution for injection or rectal use) in the care pathway for sedation in palliative care. |
